Hypertension & LVH
|
Notes from the European Society of Cardiology Congress, 2008
Left ventricular hypertrophy (LVH) regression and treatment
The findings of a new meta-analysis was presented at this conference. The presenter stated that there are flaws in
previous meta-analysis.
Part of the analysis was restricted to studies with patients on single agent antihypetensive therapy where there was direct comparison with another agent.
It was found that the only significant difference found between drugs was that
between beta-blockers and angiotensinogen receptor blockers (ARBs)- ie ARB are better than beta-blockers.
Another analysis found that beta-blockers when used as add on therapy did not cause much LVH regression.
It was also concluded that the inferiority of betablockers was more convincing than
superiority of ARBs.
All drugs did seem to reduce LVH to at least some extent.
The analysis does have limitations including due to lack of data from large studies.
|
|